Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on European News Update.
May 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | |||
5 | 6 | 7 | 8 | 9 | 10 | 11 |
12 | 13 | 14 | 15 | 16 | 17 | 18 |
19 | 20 | 21 | 22 | 23 | 24 | 25 |
26 | 27 | 28 | 29 | 30 | 31 |
June 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | ||||||
2 | 3 | 4 | 5 | 6 | 7 | 8 |
9 | 10 | 11 | 12 | 13 | 14 | 15 |
16 | 17 | 18 | 19 | 20 | 21 | 22 |
23 | 24 | 25 | 26 | 27 | 28 | 29 |
30 |
July 2025
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | |
7 | 8 | 9 | 10 | 11 | 12 | 13 |
14 | 15 | 16 | 17 | 18 | 19 | 20 |
21 | 22 | 23 | 24 | 25 | 26 | 27 |
28 | 29 | 30 | 31 |
Press releases published on July 1, 2025

Endeavour to Announce Its Q2 and Half Year 2025 Results on 31 July 2025
ENDEAVOUR TO ANNOUNCE ITS Q2 AND HALF YEAR 2025 RESULTS ON 31 JULY 2025 London, 1 July 2025 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) expects to release its Q2 and Half Year 2025 financial results on Thursday 31 July 2025, before the …

ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application
FDA 510(k) application submitted to allow marketing of the ARC-EX® System for home use in the United States CE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European Union and other countries EINDHOVEN, …

Sodexo Q3 Fiscal 2025 revenues in line with expectations
Issy-les-Moulineaux, July 1, 2025 (7am) Sodexo (Euronext Paris FR 0000121220-OTC: SDXAY) Organic revenue growth of +3.0% Fiscal 2025 expected to land at the lower end of the guidance range: Organic revenue growth between +3% and +4% Underlying operating …

Sodexo : Chiffre d’affaires du 3e trimestre de l’exercice 2025 en ligne avec les attentes
Issy-les-Moulineaux, le 1er juillet 2025 (7h00) Sodexo (Euronext Paris FR 0000121220-OTC : SDXAY) Croissance interne du chiffre d’affaires de +3,0% Exercice 2025 attendu dans le bas de la fourchette des objectifs annuels : Croissance interne du chiffre d' …

ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility
RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-approved oral therapies currently exist for this underserved population LAUSANNE, Switzerland and …

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and …

Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required …

Western Uranium & Vanadium Announces Results of AGM and Appoints New Transfer Agent
Toronto, Ontario and Nucla, Colorado, June 30, 2025 (GLOBE NEWSWIRE) -- Western Uranium …